A5113708509- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- Cancer survivorship and care
- Neuroendocrine Tumor Research Advances
- Palliative Care and End-of-Life Issues
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Neutropenia and Cancer Infections
- Breast Cancer Treatment Studies
- Childhood Cancer Survivors' Quality of Life
- Bacterial Infections and Vaccines
- BRCA gene mutations in cancer
- Chronic Myeloid Leukemia Treatments
- Nutrition and Health in Aging
- Lung Cancer Research Studies
- Head and Neck Surgical Oncology
- Airway Management and Intubation Techniques
- Teratomas and Epidermoid Cysts
- Pharmaceutical Economics and Policy
- Opioid Use Disorder Treatment
- Advanced Breast Cancer Therapies
Willows Veterinary Centre and Referral Service
2025
Icahn School of Medicine at Mount Sinai
2025
Princess Margaret Cancer Centre
2007-2023
Norton Healthcare
2007-2023
Queen's University
2009-2016
University of Alberta
1999-2014
Austin Health
2009
Dr. H. Bliss Murphy Cancer Centre
2009
The Royal Melbourne Hospital
2009
Sunnybrook Health Science Centre
2009
Patients with advanced pancreatic cancer have a poor prognosis and there been no improvements in survival since the introduction of gemcitabine 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) this is associated worse prognosis. We studied effects adding HER1/EGFR-targeted agent erlotinib to patients unresectable, locally advanced, or metastatic cancer.
Patients with advanced pancreatic cancer have a poor prognosis and there been no improvements in survival since the introduction of gemcitabine 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) this is associated worse prognosis. We studied effects adding HER1/EGFR-targeted agent erlotinib to patients unresectable, locally advanced, or metastatic cancer.
Observational studies indicate that physical activity (PA) is strongly associated with improved disease outcomes in colon cancer survivors, but a randomized controlled trial needed to determine whether the association causal and new policies promote exercise are justified.The co.21 Colon Health Life-Long Exercise Change (challenge) undertaken by National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) designed effects structured pa intervention on for survivors high-risk stage II...
The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for the who received cetuximab plus care (N = 283) or alone 274).Direct medical were collected,...
e17572 Background: Economic evaluations (EE) are routinely used by decision-makers in Canada. CADTH's “Guidelines for the Evaluation of Health Technologies: Canada” Third edition, 2006, provide guidance on conduct EEs all therapeutic products. The consistency and quality oncology variable therapeutics cancer care environment presented unique challenges decision making. Several chapters CADTH document adequately defined methods an EE. However, some required more specific to improve EEs. goal...
Abstract A 7‐year 2‐month‐old, entire, male Springer Spaniel dog was presented to the oncology service at Royal (Dick) School of Veterinary Studies for a nasopharyngeal mass. The patient underwent debulking surgery tumour under general anaesthesia, and transmylohyoid endotracheal intubation performed airway management. anaesthesia were uneventful. No complication associated with surgical site incision reported. received radiotherapy following surgery, there no sign disease recurrence in...
Abstract Introduction Sleep disturbance/disorders are common among immigrants in the United States, yet few studies focus on older Chinese Americans and their link to Alzheimer’s Disease Related Dementias (AD/ADRD). While physical mental health known affect cognition, it is unclear whether they mediate relationship between sleep disturbances cognition. This study aimed to: 1) investigate association self-reported both objective subjective cognitive functions Americans; 2) explore this...
19647 Background: The primary objective of the BCIRG 006 trial was to determine if use trastuzumab in early high-risk HER2-positive breast cancer significantly improved clinical outcomes. A secondary evaluate QOL patients receiving 2 treatments. Methods: compared adjuvant standard AC (doxorubicin/cyclophosphamide x 4 cycles) followed by docetaxel [AC-T] or trastuzumab-containing regimens, T with 1 year [AC-TH] TCarbo 6 [TCH] node positive negative (n=3222). Results: 2nd planned interim...
4609 Background: The epidermal growth factor receptor (EGFR) is a potentially important target in PC. Benefit from erlotinib (Tarceva), an oral EGFR tyrosine kinase inhibitor has been associated with the presence of skin rash. purpose this study was to determine efficacy erlotinib, dosed achieve rash, patients (pts) Methods: Erlotinib given at initial dose 150 mg/day eligible pts locally advanced (LA) or metastatic PC who had progressed were unable tolerate gemcitabine-based chemotherapy....
4002 Background: Cetuximab prolongs survival in pretreated advanced colorectal cancer (CRC) patients (pts). For these pts, the effect of palliative treatment on quality life (QOL) is also an important outcome. Methods: CO.17 was a randomized controlled trial (n=572) cetuximab combined with best supportive care (BSC) vs BSC alone pts epidermal growth factor receptor-positive CRC. Primary endpoint survival. QOL secondary using EORTC QLQ-C30 at baseline, 4, 8, 16, and 24 weeks (wks). for...
3588 Background: The NCIC Clinical Trials Group CO.17 trial, conducted with the Australasian Gastrointestinal Group, showed cetuximab monotherapy (CET vs best supportive care - BSC) improved overall (OS) and progression-free survival (PFS) maintained health-related quality of life (HRQL) in patients (pts) previously treated for advanced colorectal cancer. Correlative analyses strong relationships between CET benefits both rash development KRAS mutation status. Association is now presented by...
<h3>Abstract</h3> <h3>Objectives</h3> To examine trends in drug overdose deaths by gender, race and geography the United States during period 2013-2020. <h3>Methods</h3> We used final National Vital Statistics System multiple cause-of-death mortality files to extract crude rates gender calculate male-to-female ratios of between 2013 2020. established 2013-2019 temporal for four major types: psychostimulants with addiction potential (T43.6, such as methamphetamines); heroin (T40.1); natural...
4130 Background: The National Cancer Institute of Canada Clinical Trials Group CO.17 trial, conducted in collaboration with the Australasian Gastrointestinal Group, demonstrated cetuximab monotherapy (vs best supportive care - BSC) improved overall (OS) and progression-free survival (PFS) maintained quality life (QoL) patients previously treated for advanced colorectal cancer that expressed Epidermal Growth Factor Receptor (EGFR). We analyzed correlation between occurrence rash clinical QoL...
2067 Background: The promoter of thymidylate synthase (TS) has a variable number tandem repeats (VNTR) polymorphism and single nucleotide (SNP) within the VNTR region. have been associated with toxicity TS inhibitors in retrospective studies. SNP not studied respect to from inhibitors. suggested abolish activity USF-1 enhancer located 2nd repeat VNTR. combined effect means that pts will 2, 3 or 4 enhancers promoter. We hypothesized would predict at risk for Gr 3/4 mucositis diarrhea...
10549 Background: Breast cancer is the most frequently diagnosed malignancy among North American women, accounting for about 30% of all new cases each year. Although male breast accounts less than 1% cases, recent reports indicate significantly increasing incidence. Research suggests that men with experience serious psychologic issues including feeling masculine by having a woman’s disease, isolated rare and uncomfortable seeking or receiving support. Men may also post-surgical effects...